Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107.
Akinkuotu AC, Maduekwe UN, Hayes-Jordan A. Surgical outcomes and survival rates of colon cancer in children and young adults. Am J Surg. 2021;221(4):718–24.
Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, et al. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021;70(1):114–26.
Qaderi SM, Dickman PW, de Wilt JHW, Verhoeven RHA. Conditional survival and cure of patients with Colon or rectal Cancer: a population-based study. J Natl Compr Cancer Netw. 2020;18(9):1230–7.
Yoon J, Terman JR. MICAL redox enzymes and actin remodeling: new links to classical tumorigenic and cancer pathways. Mol Cell Oncol. 2018;5(1):e1384881.
Giridharan SS, Caplan S. MICAL-family proteins: complex regulators of the actin cytoskeleton. Antioxid Redox Signal. 2014;20(13):2059–73.
Sun Y, Jaldin-Fincati J, Liu Z, Bilan PJ, Klip A. A complex of Rab13 with MICAL-L2 and alpha-actinin-4 is essential for insulin-dependent GLUT4 exocytosis. Mol Biol Cell. 2016;27(1):75–89.
Sakane A, Honda K, Sasaki T. Rab13 regulates neurite outgrowth in PC12 cells through its effector protein, JRAB/MICAL-L2. Mol Cell Biol. 2010;30(4):1077–87.
Min P, Zhao S, Liu L, Zhang Y, Ma Y, Zhao X, et al. MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration. J Cell Mol Med. 2019;23(6):4475–88.
Zhu LY, Zhang WM, Yang XM, Cui L, Li J, Zhang YL, et al. Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition. Cancer Lett. 2015;363(1):71–82.
Ioannou MS, Bell ES, Girard M, Chaineau M, Hamlin JN, Daubaras M, et al. DENND2B activates Rab13 at the leading edge of migrating cells and promotes metastatic behavior. J Cell Biol. 2015;208(5):629–48.
Min P, Zhang L, Wang Y, Qi C, Song Y, Bibi M, et al. MICAL-L2 is essential for c-Myc Deubiquitination and stability in non-small cell lung Cancer cells. Front Cell Dev Biol. 2020;8:575903.
Vanoni MA. Structure-function studies of MICAL, the unusual multidomain flavoenzyme involved in actin cytoskeleton dynamics. Arch Biochem Biophys. 2017;632:118–41.
Gu H, Li Y, Cui X, Cao H, Hou Z, Ti Y, et al. MICAL1 inhibits colorectal cancer cell migration and proliferation by regulating the EGR1/beta-catenin signaling pathway. Biochem Pharmacol. 2022;195:114870.
Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
Qi C, Min P, Wang Q, Wang Y, Song Y, Zhang Y, et al. MICAL2 contributes to gastric Cancer cell proliferation by promoting YAP Dephosphorylation and nuclear translocation. Oxidative Med Cell Longev. 2021;2021:9955717.
Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan B, et al. CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016;14:32.
Dumitru CA, Bankfalvi A, Gu X, Zeidler R, Brandau S, Lang S. AHNAK and inflammatory markers predict poor survival in laryngeal carcinoma. Plos One. 2013;8(2):e56420.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.
Gene Ontology C. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 2021;49(D1):D325–34.
Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
Zhang Q, Xia T, Qi C, Du J, Ye C. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma. BMC Cancer. 2022;22(1):77.
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.
Yan Y, Nie K, Zheng J, Jiang X, Huang Y, Zheng Z, et al. High endothelin receptor type a expression as an independent prognostic biomarker and correlated with immune infiltrates in stomach adenocarcinoma. Cancer Manag Res. 2021;13:5013–26.
McGarry DJ, Armstrong G, Castino G, Mason S, Clark W, Shaw R, et al. MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Lett. 2021;519:226–36.
Zhou W, Liu Y, Gao Y, Cheng Y, Chang R, Li X, et al. MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma. Cancer Lett. 2020;483:75–86.
Deng W, Wang Y, Zhao S, Zhang Y, Chen Y, Zhao X, et al. MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway. J Cell Mol Med. 2018;22(6):3108–18.
Wang Y, Min P, Qi C, Zhao S, Yu M, Zhang Y, et al. MICAL2 facilitates gastric Cancer cell migration via MRTF-A-mediated CDC42 activation. Front Mol Biosci. 2021;8:568868.
Giridharan SS, Rohn JL, Naslavsky N, Caplan S. Differential regulation of actin microfilaments by human MICAL proteins. J Cell Sci. 2012;125(Pt 3):614–24.
Sakane A, Yoshizawa S, Yokota H, Sasaki T. Dancing styles of collective cell migration: image-based computational analysis of JRAB/MICAL-L2. Front Cell Dev Biol. 2018;6:4.
Miyake K, Sakane A, Tsuchiya Y, Sagawa I, Tomida Y, Kasahara J, et al. Actin cytoskeletal reorganization function of JRAB/MICAL-L2 is fine-tuned by intramolecular interaction between first LIM zinc finger and C-terminal coiled-coil domains. Sci Rep. 2019;9(1):12794.
Sakane A, Abdallah AA, Nakano K, Honda K, Ikeda W, Nishikawa Y, et al. Rab13 small G protein and junctional Rab13-binding protein (JRAB) orchestrate actin cytoskeletal organization during epithelial junctional development. J Biol Chem. 2012;287(51):42455–68.
Rahajeng J, Giridharan SS, Cai B, Naslavsky N, Caplan S. Important relationships between Rab and MICAL proteins in endocytic trafficking. World J Biol Chem. 2010;1(8):254–64.
Yamamura R, Nishimura N, Nakatsuji H, Arase S, Sasaki T. The interaction of JRAB/MICAL-L2 with Rab8 and Rab13 coordinates the assembly of tight junctions and adherens junctions. Mol Biol Cell. 2008;19(3):971–83.
Nakatsuji H, Nishimura N, Yamamura R, Kanayama HO, Sasaki T. Involvement of actinin-4 in the recruitment of JRAB/MICAL-L2 to cell-cell junctions and the formation of functional tight junctions. Mol Cell Biol. 2008;28(10):3324–35.
Terai T, Nishimura N, Kanda I, Yasui N, Sasaki T. JRAB/MICAL-L2 is a junctional Rab13-binding protein mediating the endocytic recycling of occludin. Mol Biol Cell. 2006;17(5):2465–75.
Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal Cancer. N Engl J Med. 2020;383(23):2207–18.
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.
Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127(11):4042–58.
Hwang S, Han J, Baek JS, Tak E, Song GW, Lee SG, et al. Cytotoxicity of human hepatic Intrasinusoidal CD56(bright) natural killer cells against hepatocellular carcinoma cells. Int J Mol Sci. 2019;20(7):1564.
Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–75.